Next-generation BTK inhibitors and their value in CLL
Clinical evidence supporting rituximab
Won Seog Kim
BCL2 inhibition and CLL: the role of venetoclax
Technology guiding future directions in CLL
What are the genetic and environmental risk factors for chronic lymphoblastic leukemia (CLL)?